Thromboxan

Thromboxan is not a widely recognized chemical name in standard biochemical nomenclature. In most sources the term is a misspelling or alternate transliteration of thromboxane, especially thromboxane A2 (TXA2). The following summarizes the biologically active thromboxane and notes the potential naming confusion.

Thromboxane A2 is an eicosanoid produced by platelets during COX-1–mediated metabolism of arachidonic acid. The synthesis proceeds from phospholipids to arachidonic acid, then through cyclooxygenase to prostaglandin G2/H2, and finally via thromboxane synthase to TXA2. Because TXA2 is chemically unstable, it rapidly hydrolyzes to the more stable metabolite TXB2, which is often measured in biosamples.

Function and mechanism: TXA2 acts on thromboxane receptors (TP receptors) on platelets and vascular smooth muscle, promoting platelet aggregation and vasoconstriction. In hemostasis, TXA2 reinforces platelet plug formation; in pathophysiology, excessive TXA2 contributes to thrombosis and vasoconstriction in conditions such as migraine and asthma; endothelium counterbalances TXA2 with prostacyclin (PGI2).

Clinical relevance: Antiplatelet therapy commonly inhibits TXA2 production. Low-dose aspirin irreversibly inhibits COX-1 in platelets, reducing TXA2 and decreasing thrombosis risk. Other COX inhibitors or TP-receptor antagonists have been developed to modulate TXA2 signaling. Understanding TXA2 biology informs treatments for cardiovascular disease and disorders of bronchoconstriction associated with aspirin sensitivity.